The company operates a network of Ayurvedic hospitals and clinics across India while also manufacturing and selling its own branded herbal medicines through direct-to-consumer and telemedicine channels. It primarily treats chronic conditions like kidney and liver disease using traditional Indian medical practices.
The company claims a brand-based moat supported by a large social media following and a fifth-generation practitioner legacy. However, the financial data contradicts this narrative, as EPS has collapsed by nearly 88% despite revenue growth, and cash conversion is extremely poor at 0.09, suggesting the brand does not translate into pricing power or cash flow.
Management is aggressively reinvesting in physical infrastructure, aiming to expand from 223 to 2,000 beds. While they have cleared debt using IPO proceeds, the massive disconnect between revenue growth and the collapse in earnings per share suggests that recent capital deployment has been highly value-destructive for minority shareholders.
The company's aggressive 10x expansion of physical bed capacity proved to be a classic capital allocation blunder, as the business model failed to scale profitably. While revenue grew, the underlying unit economics collapsed under the weight of high fixed costs and a marketing-heavy customer acquisition strategy that never achieved operating leverage. The massive gap between reported profits and actual cash flow eventually forced a reckoning when trade receivables became uncollectible, revealing that the 'growth' was largely an accounting fiction unsupported by real-world liquidity.
RichFakir rates KRM Ayurveda Ltd's business quality as poor — 45/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
On our model, KRM Ayurveda Ltd is trading far above our estimate of fair value (expensive on our lens); we rate its price expensive. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on KRM Ayurveda Ltd is: Avoid. We are steering clear of this one — the red flags below outweigh anything the price or numbers offer.
RichFakir's educational estimate of KRM Ayurveda Ltd's fair value is about ₹91 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →